My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1241

    1.

    Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

    Dunnwald LK, Rossing MA, Li CI.

    Breast Cancer Res. 2007;9(1):R6.

    PMID:
    17239243
    [PubMed - indexed for MEDLINE]

    2.

    Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

    Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR.

    JAMA. 2003 Jun 25;289(24):3254-63.

    PMID:
    12824206
    [PubMed - indexed for MEDLINE]

    3.

    The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.

    Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V.

    Cancer. 2008 Feb 15;112(4):737-47.

    PMID:
    18189290
    [PubMed - indexed for MEDLINE]

    4.

    Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.

    Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A.

    J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8.

    PMID:
    16264180
    [PubMed - indexed for MEDLINE]

    5.

    Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

    Parise CA, Bauer KR, Brown MM, Caggiano V.

    Breast J. 2009 Nov-Dec;15(6):593-602. Epub 2009 Sep 17.

    PMID:
    19764994
    [PubMed - indexed for MEDLINE]

    6.

    Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.

    Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI.

    Cancer. 2005 Jun 1;103(11):2241-51.

    PMID:
    15844176
    [PubMed - indexed for MEDLINE]

    7.

    Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

    Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

    Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.

    PMID:
    19256737
    [PubMed - indexed for MEDLINE]

    8.

    Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.

    Tutera AM, Sellers TA, Potter JD, Drinkard CR, Wiesner GL, Folsom AR.

    Genet Epidemiol. 1996;13(2):207-21.

    PMID:
    8722747
    [PubMed - indexed for MEDLINE]

    9.

    Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.

    Bardia A, Hartmann LC, Vachon CM, Vierkant RA, Wang AH, Olson JE, Sellers TA, Cerhan JR.

    Arch Intern Med. 2006 Dec 11-25;166(22):2478-83.

    PMID:
    17159013
    [PubMed - indexed for MEDLINE]

    10.

    Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases.

    Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP.

    Cancer. 1996 Apr 15;77(8):1465-71.

    PMID:
    8608530
    [PubMed - indexed for MEDLINE]

    11.

    Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.

    Cancer. 2008 Mar 1;112(5):995-1000.

    PMID:
    18098228
    [PubMed - indexed for MEDLINE]

    12.

    Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

    Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO.

    Breast Cancer Res Treat. 2010 Jan;119(1):53-61. Epub 2009 Feb 10.

    PMID:
    19205877
    [PubMed - indexed for MEDLINE]

    13.

    Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.

    Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Lænkholm AV, Kroman N, Ewertz M, Offersen B, Toftdahl DB, Møller S, Mouridsen HT; Danish Breast Cancer Cooperative Group.

    J Natl Cancer Inst. 2011 Sep 21;103(18):1363-72. Epub 2011 Aug 31.

    PMID:
    21881042
    [PubMed - indexed for MEDLINE]

    14.

    Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

    Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.

    Breast Cancer Res Treat. 2009 Jan;113(2):357-70. Epub 2008 Mar 7.

    PMID:
    18324472
    [PubMed - indexed for MEDLINE]

    15.

    Body weight correlates with mortality in early-stage breast cancer.

    Enger SM, Greif JM, Polikoff J, Press M.

    Arch Surg. 2004 Sep;139(9):954-58; discussion 958-60.

    PMID:
    15381612
    [PubMed - indexed for MEDLINE]

    16.

    Risk factors for hormone receptor-defined breast cancer in postmenopausal women.

    Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C.

    Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2482-8.

    PMID:
    17164374
    [PubMed - indexed for MEDLINE]

    17.

    Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women.

    Hedelin M, Löf M, Olsson M, Adlercreutz H, Sandin S, Weiderpass E.

    J Nutr. 2008 May;138(5):938-45.

    PMID:
    18424605
    [PubMed - indexed for MEDLINE]

    18.

    Diminished survival in patients with inner versus outer quadrant breast cancers.

    Gaffney DK, Tsodikov A, Wiggins CL.

    J Clin Oncol. 2003 Feb 1;21(3):467-72.

    PMID:
    12560437
    [PubMed - indexed for MEDLINE]

    19.

    Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.

    Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA.

    Cancer. 2004 Oct 1;101(7):1490-500.

    PMID:
    15378477
    [PubMed - indexed for MEDLINE]

    20.

    Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

    Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

    J Clin Oncol. 2008 Mar 10;26(8):1260-8.

    PMID:
    18323549
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filter your results:

      Find related data

      Recent activity

      You are here: NCBI > Literature > PubMed
      Write to the Help Desk